Ribociclib Medication Profile

Summary or Key Points

Ribociclib is a prescribed medication used to treat certain types of breast cancer in women. It helps slow down the growth and spread of cancer cells. Ribociclib is commonly used in combination with another cancer medication, often an aromatase inhibitor. Like any medication, Ribociclib has side effects and potential drug interactions that should be discussed with a healthcare provider.

Names of Medication

The US Brand Name for Ribociclib is Kisqali. The generic name, Ribociclib, is used to refer to the active substance in the medicine, the component responsible for its effects. The generic name (Ribociclib) is listed in parenthesis.

Pharmacologic Category

Ribociclib belongs to a category of drugs known as cyclin-dependent kinase inhibitors. Other medications in the same category include Palbociclib (Ibrance) and Abemaciclib (Verzenio).

Dosing

Ribociclib is indicated for the treatment of Hormone Receptor (HR)-positive, Human Epidermal growth factor Receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women. The usual dose is 600 mg orally (3 x 200 mg tablets) once daily for 21 consecutive days, followed by 7 days without treatment. This cycle is typically repeated every 28 days. Always consult with a healthcare provider before making changes to your treatment plan. Our telemedicine service is available to discuss adjustments.

Dosage Forms and Strengths

Ribociclib (Kisqali) comes in the form of a tablet, available in three strengths: 200 mg, 400 mg, and 600 mg.

Administration Instructions

Ribociclib tablets should be taken orally, with or without food, at approximately the same time each day. If a dose is missed or vomiting occurs following a dose, no additional dose should be taken that day. The next prescribed dose should be taken at the usual time.

Adverse Reactions and Side Effects

Ribociclib may cause several side effects. Common ones include nausea, fatigue, diarrhea, hair loss, vomiting, constipation, headache, and cough. More severe side effects include low white blood cell counts, liver problems, abnormal heartbeat, and serious skin reactions. These are not all the possible side effects. Seek medical attention immediately if any unusual symptoms occur.

Contraindications

A contraindication is a condition or factor that serves as a reason to withhold a certain medical treatment due to potential harm or risk to the patient. Ribociclib should not be used in patients with known hypersensitivity to Ribociclib or to any of its ingredients. It’s also contraindicated in patients with prolonged QT interval, a heart rhythm disorder, because Ribociclib can cause QT prolongation and serious heartbeat abnormalities.

Drug to Drug Interactions

Several medications may interact with Ribociclib, altering its effectiveness or causing additional side effects. Some of these include strong CYP3A inhibitors like Ketoconazole (Nizoral), and strong CYP3A inducers like Rifampin (Rifadin). Always consult with your healthcare provider about potential interactions with other drugs.

Riboc iclib in Pregnancy

It is not recommended to take Ribociclib during pregnancy. Ribociclib can harm the unborn baby or cause birth defects. It’s important to use effective contraception during treatment and for some time after the last dose. Talk to your healthcare provider about family planning and contraception.

Ribociclib while Breastfeeding

It’s recommended not to breastfeed while taking Ribociclib and for at least 21 days after the last dose because this medication may pass into breast milk and harm the baby. Always consult with your healthcare provider to decide the best course of action.

Estimated Cost of Medication

The cost for Ribociclib (Kisqali) can vary widely, but a typical cost for a 30-day supply without insurance is around $12,000, according to GoodRx. Prices can vary depending on the pharmacy and location. Check with your insurance provider to understand your coverage and co-payments.

Possible Alternatives

Alternative treatments for HR-positive, HER2-negative advanced or metastatic breast cancer may include other cyclin-dependent kinase inhibitors like Palbociclib (Ibrance) or Abemaciclib (Verzenio). Other possible treatments include hormonal therapies, chemotherapy, targeted therapies, and immunotherapy. Lifestyle changes such as eating a healthy diet, regular exercise, and quitting smoking may also improve overall health. Discuss these options with a healthcare provider. Our telemedicine service is available to provide personalized advice on treatment alternatives.

Recent Updates on Ribociclib Research

Recent studies have shown promising results for Ribociclib in combination with other therapies for the treatment of early-stage breast cancer. Ongoing research is looking at the effectiveness of Ribociclib in treating other types of cancer. It’s important to discuss with your healthcare provider about new research and whether it might impact your treatment plan.

Brief Legal Disclaimer: This article is for informational purposes only and not intended as medical advice. Always consult a healthcare professional for diagnosis and treatment. Reliance on the information provided here is at your own risk.